Airborne, Inc. company makes a dietary supplement that contains herbal extracts, vitamins, electrolytes, amino acids, and antioxidants meant to boost the immune system. The effervescent tablets come in four flavors and a powdered formulation to be added to water. The products are sold nationwide in pharmacies, supermarkets, and mass merchant retailers such as Costco, CVS Caremark, Target, and Wal-Mart. Airborne was established in 1997 by former second-grade teacher Victoria Knight-McDowell. Private equity investors GF Capital Management holds a majority of the company.

Teva Neuroscience, Inc. engages in the development, registration, and marketing of neurological products in North America. It offers COPAXONE, a glatiramer acetate injection that reduces relapses in people with relapsing-remitting multiple sclerosis; and AZILECT, a rasagiline tablet for the treatment of the signs and symptoms of Parkinson disease. Teva Neuroscience, Inc. was formerly known as Teva Marion Partners and changed its name to Teva Neuroscience, Inc. in February, 2001. Teva Neuroscience, Inc. was founded in 1995 and is based in Kansas City, Missouri with an additional office in Montreal, Canada. It has a facility in Horsham, Pennsylvania. As per the transaction announced on 2/14/2001, Teva Neuroscience, Inc. is a subsidiary of Teva Pharmaceutical Industries Limited.

ImaRx Therapeutics, Inc. company was founded in 1999. ImaRx Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the development of therapies for stroke and other vascular disorders, using its microbubble technology. Its lead program, SonoLysis, involves the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The MRX-801 microspheres are a proprietary formulation of a lipid shell encapsulating an inert biocompatible gas. Discontinued operations In September 2008, the company divested its urokinase business to Microbix.

Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

CEDRA is a contract research organization, deep in the heart of Texas. CEDRA conducts phase I-IV clinical drug trials at its facilities in Austin and San Antonio, including general pharmacodynamics (what a drug does to a live human body) and pharmacokinetics (what a live human body does to a drug). The company also performs bioequivalency studies for generic pharmaceutical makers. It has experience in testing drugs ranging from allergy medicines to pain management and Parkinson's drugs. Its research customers include pharmaceutical and biotechnology drug makers, as well as the federal government. CEDRA is a division of Worldwide Clinical Trials.

Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California. Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

Apex Healthcare Berhad Company makes, markets, and distributes generic pharmaceuticals and other health care products to customers in Malaysia, Singapore, Indonesia, and China. Subsidiary Xepa-Soul Pattinson (Xepa SP), the company's manufacturing arm, is Malaysia's largest generic drug maker with products including antibiotics, corticosteroids, and neuromuscular agents in tablet, capsule, liquid, cream, and powder formulations. Xepa-SP also makes nutritionals (vitamins) and surgical supplies. The company distributes its own products and those of other manufacturers to wholesale and retail customers through subsidiaries ABio, Apex Pharmacy Marketing, and Apex Pharma.

Ranbaxy Laboratories Limited company is India's largest drug manufacturer, as well as a top global generics producer. Anti-infectives amoxycillin and ciprofloxacin, and cardio drug simvastatin are among Ranbaxy's top sellers; all come in several administration forms. The company also addresses gastrointestinal, musculoskeletal, and central nervous system disorders, as well as diabetes, pain, allergies, and HIV/AIDS. Its R&D focus includes new forms of existing drugs and metabolic disease treatments. The company also has a groundbreaking anti-malarial candidate in late-phase trials. Japanese drugmaker Daiichi Sankyo owns a controlling stake in Ranbaxy.

Medicure Inc., (Medicure) is a biopharmaceutical company engaged in the research and development and commercialization of human therapeutic. The Company's primary focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) in the United States and its territories through its United States subsidiary, Medicure Pharma Inc. The Company's primary research and development program of focus is the clinical development of TARDOXAL (product previously referred to as AVASTREM) for neurological disorders, although the Company continues to investigate and advance certain other product opportunities.

Capellon was founded in 1999. Capellon Pharmaceuticals is helping curb the common cold. Capellon Pharmaceuticals company's product portfolio includes Liquibid, Rescon, and Tussi-bid, prescription remedies for cough and congestion. Other products target various allergies as well as respiratory, gastrointestinal, and bladder ailments. Capellon concentrates its efforts on marketing products it already has and acquiring products useful to it current customer base. With an intense focus on growth it looks for partners with whom it can co-promote new drugs whenever possible.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.